Overview
Target Cells is a biotechnology start-up founded in 2023 that develops applications of human stem cells for tissue repair, especially heart regeneration. In collaboration with Jagiellonian University, it is validating the CardioBind assay, which evaluates stem-cell binding to heart tissue in vitro.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 1 of 2 financial statements was filed late (for 2023, 1 day late).
- 2025not filed
- 202414/07/2025
- 202316/07/2024
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Offer
- Stem cell research
- Cell binding tests
- In vitro tests
- Heart regeneration research
Website technology
- Website
- WordPress
- Elementor
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the company is represented by 2 (two) members of the management board jointly, or by a member of the management board together with a commercial proxy. If a Vice-President of the Management Board is appointed by the fund, the representation of the company will in every case require the participation of the Vice-President of the Management Board appointed by the fund (i.e. joint representation with the Vice-President of the Management Board appointed by the fund).
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Robin Mcwherter | 32 | $432.20 | 11.4286% |
| 84 | $1,134.52 | 30% | |
Catherine Anne Phillips | 32 | $432.20 | 11.4286% |
Targacell Corporation | 70 | $945.43 | 25% |
Ewa Katarzyna Zuba Surmaage 51 | 56 | $756.35 | 20% |
Others | 6 | $81.04 | 2.1428% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2023-04-07.
79 1050 1445 1000 0090 8208 1754
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 19, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Marszałek Województwa Małopolskiego | |
| Mar 30, 2022 | Aid for SME access to finance — aid for start-ups | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-05-01 | STUDIES OF THE STABILITY, SPECIFICITY AND MOLECULAR COMPOSITION OF THE INNOVATIVE CARDIOBIND TEST ASSESSING THE ABILITY OF STEM CELLS TO BIND TO HEART TISSUE IN VITRO FOR USE IN PERSONALIZED MEDICINE | $63,881$63,881 | European Funds for Małopolska 2021-2027 |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Awtmsp. z o.o. | $123,062.45 | awtm.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| OPTI Gsp. z o.o. | $34,289.31 | optig.pl | ||
| SimplicardiacS.A. | $28,951.71 | simplicardiac.com | ||
| Exomedissp. z o.o. | $26,633.41 | exomedis.com | ||
| InventroS.A. | $25,971.59 | inventro.co | ||
| Boneregsp. z o.o. | $25,113.01 | bonereg.com | ||
| Biotransplant Researchsp. z o.o. | $22,953.29 | biotransplant.pl | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl | ||
| Bio2materialssp. z o.o. | $14,121.59 | bio2materials.com |
Change history
| Date | Event | |
|---|---|---|
| 2023-06-07 | Share capital increase (9,800.00 PLN → 14,000.00 PLN) | |
| 2023-02-22 | Entered in the register |
FAQ
Last updated: 2026-08-19